Cytos Biotechnology AG / Key word(s): Change of Personnel
27.10.2014 18:00

Release of an ad hoc announcement pursuant to Art. 53 KR

---

Cytos Biotechnology Ltd announces change in Executive Board
Schlieren (Zurich), Switzerland, October 27, 2014 - Cytos Biotechnology Ltd. (SIX:CYTN) ("Cytos" or the "Company") announced today that Mr. Matthias Alder, Executive Vice President Corporate Development and Legal Affairs, resigns from his function effective as of October 27, 2014.
The departure of Mr. Alder follows in the course of the winding down of key operational activities of the Company. Mr. Alder has agreed to continue his service to the Company as a consultant until February 28, 2015 to complete ongoing projects and facilitate the transition of his responsibilities.

For further information, please contact: 

Cytos Biotechnology Ltd 
Harry Welten, MBA 
Chief Financial Officer 
Tel: +41 44 733 46 46 
harry.welten@cytos.com 

About Cytos Biotechnology Ltd 

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements 
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com



+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=IERDRGWDVW Document title: Cchange in Executive Board


27.10.2014 News transmitted by EQS Schweiz AG. 
The issuer is responsible for the contents of the release.
EQS publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1'300 listed companies. 
The Swiss news archive can be found at www.equitystory.ch/news

---

 
Language:               English
Company:                Cytos Biotechnology AG
                        Wagistr. 25
                        8952 Schlieren
                        Switzerland
Phone:                  +41 44 733 4747
Fax:                    +41 44 733 4740
E-mail:                 info@cytos.com
Internet:               www.cytos.com
ISIN: CH0011025217, CH0029060735 Valor:                  -
Listed: Freiverkehr in Berlin, München, Stuttgart; Frankfurt in Open Market ; SIX  
End of Announcement EQS Group News-Service  

---